Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid ...
COLUMBUS , Ohio – A type of chromosome change that was thought to predict a good response to treatment in patients with acute myeloid leukemia (AML) might actually signal the need for a different ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback